Trials / Conditions / Hypereosinophilic Syndrome

Hypereosinophilic Syndrome

26 registered clinical trials studyying Hypereosinophilic Syndrome — 5 currently recruiting.

Status	Trial	Sponsor	Phase
Recruiting	Dupilumab as Add-On Therapy for Hypereosinophilic Syndrome With Partial Clinical Response to Eosinophil-Deplet NCT06477653	National Institute of Allergy and Infectious Diseases (NIAID)	Phase 2
Recruiting	Depemokimab in Participants With Hypereosinophilic Syndrome, Efficacy, and Safety Trial NCT05334368	GlaxoSmithKline	Phase 3
Completed	Study in Pediatrics With HypEREosinophilic Syndrome (SPHERE) NCT04965636	GlaxoSmithKline	Phase 3
Active Not Recruiting	A Phase III Study to Evaluate the Efficacy and Safety of Benralizumab in Patients With Hypereosinophilic Syndr NCT04191304	AstraZeneca	Phase 3
Recruiting	Ruxolitinib in Treating Patients With Hypereosinophilic Syndrome or Primary Eosinophilic Disorders NCT03801434	William Shomali	Phase 2
Recruiting	Natural History of Hypereosinophilia and Hypereosinophilic Syndromes NCT04018118	University Hospital, Lille	—
Completed	A Multi-center, Open-label Extension, Safety Study of Mepolizumab in Subjects With Hypereosinophilic Syndrome NCT03306043	GlaxoSmithKline	Phase 3
Completed	Efficacy and Safety Study of Mepolizumab in Subjects With Severe Hypereosinophilic Syndrome (HES) NCT02836496	GlaxoSmithKline	Phase 3
Unknown	Eosinophilia Diagnosis NCT02581514	University Hospital, Limoges	N/A
Unknown	Study to Evaluate Safety and Efficacy of Dexpramipexole (KNS-760704) in Subjects With Hypereosinophilic Syndro NCT02101138	National Institute of Allergy and Infectious Diseases (NIAID)	Phase 2
Completed	Steroid Treatment for Hypereosinophilic Syndrome NCT01524536	National Institute of Allergy and Infectious Diseases (NIAID)	Phase 4
Completed	Identification of New Markers in the Hypereosinophilic Syndrome NCT01713504	University Hospital, Lille	N/A
Completed	Dasatinib as Therapy for Myeloproliferative Disorders (MPDs) NCT00255346	M.D. Anderson Cancer Center	Phase 2
Recruiting	A Longitudinal Study of Familial Hypereosinophilia (FE): Natural History and Markers of Disease Progression NCT00091871	National Institute of Allergy and Infectious Diseases (NIAID)	—
Completed	A Study of Oral AMN107 in Adults With Chronic Myelogenous Leukemia (CML) or Other Hematologic Malignancies NCT00109707	Novartis Pharmaceuticals	Phase 1 / Phase 2
Completed	Efficacy of Imatinib Mesylate in Hypereosinophilic Syndromes NCT00787384	Northern Italy Leukemia Group	Phase 2
Terminated	Open-Label Extension Of Intravenous Mepolizumab In Patients With Hypereosinophilic Syndrome NCT00097370	GlaxoSmithKline	Phase 3
Completed	Imatinib Mesylate in Patients With Various Types of Malignancies Involving Activated Tyrosine Kinase Enzymes NCT00171912	Novartis Pharmaceuticals	Phase 2
Completed	Intravenous Mepolizumab In Subjects With Hypereosinophilic Syndromes (HES) NCT00086658	GlaxoSmithKline	Phase 3
Terminated	Phase II Gleevec Idiopathic Hypereosinophilic Syndrome NCT00230334	Steven E. Coutre	Phase 2
Unknown	Study of STI571 in the Treatment of Patients With Idiopathic Hypereosinophilic Syndrome (HES) and Eosinophilic NCT00276926	University of Bologna	Phase 2
Active Not Recruiting	Tyrosine Kinase Inhibition to Treat Myeloid Hypereosinophilic Syndrome NCT00044304	National Institute of Allergy and Infectious Diseases (NIAID)	Phase 2
Terminated	A Study to Determine the Safety and Efficacy of Imatinib Mesylate in Patients With Idiopathic Hypereosinophili NCT00171860	Novartis Pharmaceuticals	Phase 2
Completed	Anti-Interleukin-5 Antibody to Treat Hypereosinophilic Syndrome NCT00017862	National Institute of Allergy and Infectious Diseases (NIAID)	Phase 2
Completed	Therapy of HES, PV, Atypical Chronic Myelocytic Leukemia (CML) or Chronic Myelomonocytic Leukemia (CMML), and NCT00038675	M.D. Anderson Cancer Center	N/A
No Longer Available	This Record Contains Information About the Mepolizumab Compassionate Use (CU) Product Activities: 104317: CU a NCT00244686	GlaxoSmithKline	—